treatment success and the course of the disease. Furthermore, information on the cognitive status can also indicate the need for rehabilitative procedures, or it can direct treatment choices. By means of cognitive monitoring, neuropsychology allows for quality and outcome control of medical interventions striving for an improved individual medical care [2] .
Since the mutual relationship between pathology, epilepsy, and cognition has become increasingly recognized, cognition in people with new-onset epilepsy has been studied more intensively. In 2011, this issue was identified as a theme of major importance for neuropsychological research in the field of epilepsy [8] . Beforehand it is important to point out that a careful distinction needs to be made between research relating to children and adults. In children, neuropediatric services and parents are concerned with brain and mental development as soon as a patient is diagnosed with epilepsy. For a review focusing on cognition in pediatric patients with new-onset seizures please see Hermann et al. [9] . In children it has been demonstrated how early assessment allows for the monitoring of the subsequent course of epilepsy [10, 11] . This may well serve as a model for adult epileptology. However, in adults it is still common practice at the stage of diagnosis to explore the etiology of seizures and focus on rapid seizure control but not to take account of comorbidities such as cognitive difficulties.
For this review we performed a literature search (medline) for original articles investigating cognition in ''untreated'' ''adult patients'' with ''new-onset epilepsy'' or ''newly-diagnosed epilepsy''. Only studies with an objective cognitive assessment were considered. A total of 11 studies met these criteria. Most of them addressed at least attention and memory and reported respective impairments in these domains [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] (for overview see Table 2 ). However, the studies differed considerably in regard to patient selection, sample sizes, etiologies, assessment tools, the question of any pretreatment, and most importantly in regard to the duration of untreated epilepsy. A point of major importance is that most studies investigated newly diagnosed patients and not patients with new-onset epilepsies, emphasizing the need for a clear terminology [23] . Indeed the mean duration of epilepsy in the different patient cohorts ranged from 92 days to 7 years. Even the newly diagnosed patients of the SANAD study presented with a mean epilepsy duration of 5 years [18] . The same is true for an early study performed at our center comparing the cognitive effects of first treatment on lesional versus non-lesional patients [22] . This means that the neuropsychological findings from such studies cannot tell us much about new-onset epilepsy. Another factor which needs to be considered is age at the onset of epilepsy, which ranges on average between 27 and 71 years. The age at the onset of epilepsy is strongly connected to its etiology. Therefore the results obtained in early versus late onset epilepsies can hardly be compared without taking pathology and the interaction of pathology with the maturing versus aging brain into consideration. In the light of the increasing incidence of epilepsy with older age, a recent study investigated elderly patients with new-onset epilepsy aged between 60 and 95 years. As expected elderly patients showed greater impairments than the younger sample [20] .
Some studies analyzed patients without evidence of brain pathology in order to disclose the sole effect of active epilepsy on cognition [12, 14, 18] . One study considered epilepsy syndromes and compared the neuropsychological results between idiopathic, symptomatic and cryptogenic epilepsies [19] : Among these subtypes, symptomatic epilepsies presented with the worst performance in executive function. Finally, most studies simply compared the cognitive performance of patients with newly diagnosed epilepsy and healthy controls on a group level. Only five of the 11 studies assessed more than 100 patients, a minority had larger reference groups of healthy subjects, and only six studies provide prevalences/frequencies of cognitive deficits on an individual level according to normative data or healthy controls [18] [19] [20] . Taylor et al. report impaired performance in 1-18% of all measures of the employed test battery [18] . Fifty-four percent of the patients versus 21% of the healthy controls were impaired in at least one test score. A study in 247 middle-aged patients with newonset epilepsy found impairments in attention and memory in 48-49% of the sample [19] . Less than one third was unimpaired in both domains. Subjective deficits in the respective domains were complained by 25-29% of the patients only. This indicates an underreporting of cognitive deficits at this early stage of epilepsy. Comparable underreporting was evident in 257 elderly patients with new-onset epilepsy [20] : The prevalence of objective deficits in executive function was 58%, whereas subjective deficits were reported in only up to 27% of the patients. The independent observation in two studies that cognitive problems were underreported when compared to objective assessment may be interpreted in a way that in the patients' view and at that early stage of the disease the diagnosis of seizures and their expected consequences are of pressing relevance. In chronic epilepsies cognitive complaints are much more frequent [24, 25] .
The finding that cognitive-behavioral deficits may precede seizure onset [26] , raises the question of whether there is a bidirectional relationship between the cognitive deficits and epilepsy. It is clear that people with epilepsy have a higher risk of cognitive deficits. But do people with cognitive impairment also have a higher risk of developing epilepsy? Although this is rather an epidemiological question, one may pursue a more theoretical approach to answer this question. First of all, epilepsy is a dysfunction of the brain associated with hyperexcitability leading to recurrent seizures. In symptomatic epilepsies, the dysfunction is caused by an epileptogenic lesion. Depending on its etiology and pathology, such a lesion may exist for a long time before the occurrence of the first seizure (cf. latent period in temporal lobe epilepsy with hippocampal sclerosis). Since the lesion itself can cause cognitive impairments, it would be not surprising that patients with new-onset symptomatic epilepsy exhibit a cognitive deficit consistent with the localization, lateralization and extent of the lesion (cave: very early brain damage may additionally affect development on a more global level thus causing intellectual disability). Moreover, one cannot rule out that covert epileptic dysfunction affects cognition even before the first overt seizure, as may be observed with transitory cognitive impairment due to interictal epileptic discharges [27] . Last but not least, psychiatric disturbances that negatively affect cognition may also precede or even promote epilepsy. For instance, there are studies indicating a bidirectional relationship between depression and epilepsy [28, 29] . In addition, it needs to be considered that the new diagnosis of epilepsy may have adverse effects on the patient's mood and due to this also on cognitive performance. However, one study in new-onset epilepsies found no correlation between the self-rated impact of the diagnosis on psychic well-being and objective cognitive performance [19] . In summary, the current evidence from studies in newly diagnosed and new-onset epilepsies show that cognitive deficits are already very common at epilepsy onset. An important and unanswered question is whether the cognitive impairment resulting from acquired or developmental cerebral lesions is a marker for the risk of future epilepsy (or epileptogenesis). Table 1 summarizes the potential factors that affect cognition prior to and at epilepsy onset as well as in the time after the development of seizures. It demonstrates, how difficult it is to isolate the impact of an individual factor on cognition. The most discriminative information can be provided by intraindividual follow-up examinations taking account of treatment changes and variations in seizure control [30] .
In new-onset symptomatic/structural epilepsy, the cognitive profile at epilepsy onset is primarily determined by the characteristics of the underlying brain lesion (time of damage/onset, extent, site, and side), eventual interictal epileptic discharges, and psychiatric problems. Individual patient characteristics and related differences in reserve capacities and neural plasticity need to be considered as well.
In idiopathic generalized epilepsies, genetically mediated alterations of nerve cell proteins (e.g. subunits of ion channels) are assumed to enhance neuronal excitability. Gross structuralmorphological brain abnormalities are usually not present. Here, cognitive problems are primarily caused by dynamic epileptic dysfunction, and also by secondary behavioral and psychiatric problems. Such problems may precede the first seizure, leading to dynamic and variable cognitive deficits as compared to the more stable lesion-related impairments. Nevertheless, they may have, even if reversible, a negative impact on cognitive development in general.
The high prevalence of objective cognitive deficits, even at the onset of epilepsy, the underreporting of cognitive problems by the patient, and the increasing number of factors contributing to cognitive dysfunction with more chronic epilepsy and its treatment call for routine neuropsychological baseline assessments soon after the onset/diagnosis, at least before treatment is initiated. As outlined above, such a baseline assessment is a prerequisite for valid repeat evaluations undertaken to reflect the course of the disease and treatment success. Moreover, the baseline assessment may direct drug choice and can be taken as an early indicator of the need of supportive or rehabilitative care. However, it is still very uncommon for epilepsy services to offer baseline cognitive assessments at the time of the diagnosis nor subsequent cognitive monitoring as a matter of routine. Cognitive assessment is often not reflected in the cost structure of health care providers, and it is, at present, mostly limited to tertiary epilepsy centers. Unfortunately, most patients with new-onset seizures will in first instance see a general practitioner, resident neurologist or an acute care hospital without any or only limited and non-specialized neuropsychological service. One possible solution would be to establish clinics specializing in newonset epilepsies which offer sufficient neuropsychological expertise to provide baseline and early follow-up assessments (for example as an extension of tertiary epilepsy centers). An alternative would be to improve the conditions of ambulatory neuropsychological services. The actual situation, at least in Germany, is quite disappointing, both in terms of financing and with regard to professional policy [31] . Neuropsychology can provide valid and reliable tools for quality and outcome control of medical interventions. This has been demonstrated particularly in the context of epilepsy surgery but also in the context of medical treatment and pharmaceutical drug trials. Disseminating this potential across institutions and countries remains a major challenge. European initiatives such as EBrain (www.ebrainjnc.com), or European networks like E-PILEPSY (www.e-pilepsy.eu/) which aim at a harmonization of diagnostic procedures and a common web-based platform for European epilepsy centers may represent a first important step towards a more routine use of neuropsychological assessment.
